Nature Communications · 2015 · 93 citations · 35 references
PharmacyMedicinal ChemistryPharmacologyDrug DeliveryDrug DiscoveryProdrug DesignAntiviral PharmacologyAntiviral Prodrug DesignAntiviral TherapyNucleotide MetabolismLipophilic ProdrugsNucleoside Analog SynthesisNucleoside AnalogsNucleoside Analogue AntiviralsNucleoside ModificationNucleoside Reverse Transcriptase InhibitorsNucleotide Analogue ProdrugsReverse Transcriptase Inhibitor Prodrugs
The antiviral activity of nucleoside reverse transcriptase inhibitors is often limited by ineffective phosphorylation. We report on a nucleoside triphosphate (NTP) prodrug approach in which the γ-phosphate of NTPs is bioreversibly modified. A series of TriPPPro-compounds bearing two lipophilic masking units at the γ-phosphate and d4T as a nucleoside analogue are synthesized. Successful delivery of d4TTP is demonstrated in human CD4(+) T-lymphocyte cell extracts by an enzyme-triggered mechanism with high selectivity. In antiviral assays, the compounds are potent inhibitors of HIV-1 and HIV-2 in CD4(+) T-cell (CEM) cultures. Highly lipophilic acyl residues lead to higher membrane permeability that results in intracellular delivery of phosphorylated metabolites in thymidine kinase-deficient CEM/TK(-) cells with higher antiviral activity than the parent nucleoside.
35
P A Furman, James A. Fyfe, M H St Clair et al. · Proceedings of the National Academy of Sciences · 1986 · 1.3K citations · Full text
Prodrugs of Phosphates and Phosphonates
Scott J. Hecker, Mark D. Erion · Journal of Medicinal Chemistry · 2008 · 412 citations
Jan Balzarini, Piet Herdewijn, Erik De Clercq · Journal of Biological Chemistry · 1989 · 340 citations · Full text
Jan Balzarini, Rudi Pauwels, Masanori Baba et al. · Biochemical Pharmacology · 1988 · 185 citations